Pregabalin Addiction: Case Report of a Young Adult by Nitin Chaudhary & Sapna Jain
International Healthcare Research Journal 2020;4(3):60-63.  
 
 
 
 
 
 
INTRODUCTION 
Pregabalin is a drug that exerts anticonvulsant, 
analgesic and anxiolytic effects on animal models and 
has a high affinity for the voltage-dependent calcium 
channels.1 It decreases the influx of calcium induced 
by depolarization and thus reduces the emissions of 
numerous excitatory.1 The prescribing indications 
include fibromyalgia, post herpetic neuralgia and 
neuropathic pain after spinal cord injury or due to 
diabetes mellitus.2 It is not approved for generalized 
anxiety disorders3 but is often used off-labelly for 
psychiatric and addictive disorders such as insomnia, 
obsessive-compulsive disorder, post-traumatic stress 
syndrome, anxiety in schizophrenia, the treatment of 
benzodiazepine withdrawal and dependence as well 
as the prevention of relapse in alcohol dependence.4-11 
It has also been shown the benefit of pregabalin in 
reducing the opioid abstinence syndrome. 12,13  
 
In 2010, on the basis of data analyzed from the 
Swedish national adverse drug reactions register, it 
was concluded that pregabalin was likely to be 
associated with a potential for abuse.14  Despite the 
increasing evidence of abuse, pregabalin is 
increasingly being prescribed. A 2012 report in the 
United Kingdom noted that the prescribing of 
pregabalin had increased by 350% over the previous 
five years15 The potential risk of abuse and addiction, 
and of the risks of liver and hematological toxicity 
were published in 201216 and recently in 2019, another 
manuscript warned about the risk of pregabalin-
related suicide.17 As pregabalin is being studied as a 
treatment in addiction, especially for the treatment of 
benzodiazepine  withdrawal10  and for  the prevention 
 
 
 
 
of relapse in alcohol dependence11, assessment of its 
potential for addiction is of major interest. As 
pregabalin has been considered to have a low 
potential for abuse, many healthcare professionals 
don’t take this product-use issue much into account 
when prescribing. However, several cases have been 
published and a few professionals are concerned 
about the risks and limitations of prescribing this 
drug. This facilitates the early detection of 
problematic developments before they become a 
major problem. Other data are necessary in order to 
identify risk factors for pregabalin abuse and 
dependence to optimize its medical indications and 
prescribing practices. We present a case of a young 
adult who presented himself with a request of 
pregabalin withdrawal.  
 
CASE REPORT 
A 25 year old male working as a sales representative 
with a telecom company visited us after being 
referred from his company panel doctor for 
pregabalin withdrawal. He had been taking between 
1.8 g of pregabalin daily for a year with no other 
associated drug use. He had tried to stop the drug few 
times, but withdrawal symptoms appeared every 
time. On further questioning he detailed that the 
symptoms included sweating, tremors, diarrhea, 
asthenia, joint pain and a craving to start pregabalin 
again, had appeared each time. His history included 
Marijuana abuse and opiate misuse that started 
during high college days till he started working at the 
age of 23. He also had a history of hospitalization due 
to  alcohol  dependence multiple times during college  
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days. He claimed to have tried a few unknown drugs 
by injection. He had only tried buprenorphine had 
been abstinent from opiates since. He had no other 
somatic or psychiatric history and there was no 
history of addiction or psychiatric disorder in his 
family. He started taking pregabalin after he was 
suggested by a college senior regarding its potential 
for helping in management of Marijuana and opioid 
withdrawal. He started taking pregabalin 300 mg 
once in a day. This helped him to decrease using 
marijuana but after a few months he increased the 
dose to twice daily as he wanted to quit marijuana 
completely. Gradually he increased the dose to 6 
tablets in 3 divided doses per day.   
 
The sought-after effects were calmness, improved 
sociability, a feeling of well-being and relaxation and 
an improvement in sleep. We hospitalized him and 
gradually reduced the doses, decreasing by 100 mg 
per day in the with daily dispensing. During 
hospitalization, the patient had a very strong desire 
to use pregabalin and requested treatment to help 
him; he also complained of gastrointestinal problems, 
insomnia, muscle and joint pain, sweating and 
anxiety. Amisulpride and chlorpromazine were 
started. Gradually decreasing benzodiazepine 
treatment was introduced for the craving. He 
sometimes showed a desire for a single pregabalin 
dose.  High dosage buprenorphine substitution 
treatment was introduced. His condition got much 
better and he was discharged. The withdrawal 
symptoms were no longer present at the time of 
discharge. He was stable for several months before 
losing for follow up. 
 
DISCUSSION 
Abuse and dependence of many drugs has come up in 
the past few decades. The euphoric effect of 
pregabalin can be considered as the main reason 
behind its abuse. Experiencing euphoria appears to 
be a dose-dependent side effect of pregabalin which 
encourages some patients to ingest large doses and 
appears to be a transient side effect. Supra-
therapeutic doses may produce sedation, 
dissociation, numbness, disinhibition, improved 
sociability, and auditory and visual hallucinations.18,19 
In our case, pregabalin was initiated with the aim of 
coming off another substance, but the initial 
withdrawal ultimately turned into a new dependence. 
The subject succeeded in withdrawing from 
pregabalin but required management based on the 
prescribing of opioid substitution treatment. 
Pregabalin abuse typically involves supra-therapeutic 
doses, often clearly exceeding the maximum 
recommended dose of 600 mg administered in 
divided doses. Abusers may continue to increase the 
dose because tachyphylaxis rapidly develops.18 
Although most take these drugs orally, other routes 
of administration have been reported: injection, 
smoking or inhalation of crushed tablets, rectal or 
parachuting.20,21 There are more cases of pregabalin 
dependence than of abuse.  
 
Most of the patients developed withdrawal symptoms 
on stopping pregabalin. Of the disorders related to 
substance use, the use of opiates is the most 
significant risk factor. In Germany, 12.1% of the 
patients treated for opioid dependence were abusing 
pregabalin compared to 2.7% of the patients treated 
for addictions to substances other than opiates.22 
Similarly, in a population of former prisoners, those 
with disorders related to opioid use were more likely 
to abuse pregabalin (26%) than those with a disorder 
related to the use of non-opioid substances (4%).23-26 
In most cases, pregabalin is initially been prescribed 
to treat a medical condition, which suggests that the 
development of addictive behaviors associated with 
pregabalin may also occur in the context of normal 
medical treatment. Moreover, it is being used for 
many unapproved indications.  
 
The management of the patients varies greatly from 
one patient to another, hospitalization and associated 
treatment may or may not be required. There is no 
consensus on the therapeutic management of 
pregabalin withdrawal. There has clearly been an 
increase in the frequency of cases of pregabalin abuse 
or dependence in recent years.23,27 This observation 
probably relates to both an increase in reports, given 
the increased awareness of pregabalin’s potential for 
addiction, and a real increase in the incidence of 
pregabalin abuse or dependence. Drug abuse or 
dependence may increase for some time before it 
reaches the threshold for reporting.  
 
CONCLUSION 
Pregabalin addiction may have reached the clinical 
detection threshold and the request for treatment is 
likewise increasing. There is a need to explore about 
certain characteristics of pregabalin misuse and 
addiction. The pharmacokinetic aspects of pregabalin 
need to be considered when assessing its potential for 
dependence. The current literature suggests an 
increase in pregabalin abuse. There is need for a 
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treatment specifically for problems associated with 
pregabalin use. The case presented in this article 
suggests that pregabalin should be prescribed with 
caution in patients with a history of addiction, 
especially to opiates. This potential for abuse is even 
more significant as pregabalin is being used as a 
treatment of another drug addiction. Large sample 
studies are required to assess the Risk factors 
associated with the development of addictive 
behavior with pregabalin. There is also a need to 
propose an appropriate management for the same. 
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